A 16-Month Community-Based Intervention to Increase Aspirin Use for Primary Prevention of Cardiovascular Disease

被引:14
|
作者
Oldenburg, Niki C. [1 ]
Duval, Sue [2 ]
Luepker, Russell V. [2 ]
Finnegan, John R. [2 ]
LaMarre, Heather [2 ]
Peterson, Kevin A. [2 ]
Zantek, Nicole D. [2 ]
Jacobs, Ginny [2 ]
Straka, Robert J. [2 ]
Miller, Karen H. [2 ]
Hirsch, Alan T. [2 ]
机构
[1] Univ Minnesota, Sch Med, Div Cardiovasc, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Minneapolis, MN 55455 USA
来源
PREVENTING CHRONIC DISEASE | 2014年 / 11卷
关键词
LOW-DOSE ASPIRIN; CORONARY-HEART-DISEASE; EVENTS; PROGRAMS; OUTCOMES; PEOPLE; ADULTS;
D O I
10.5888/pcd11.130378
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Introduction Cardiovascular diseases are the leading causes of disability and death in the United States. Primary prevention of these events may be achieved through aspirin use. The ability of a community-based intervention to increase aspirin use has not been evaluated. The objective of this study was to evaluate an educational intervention implemented to increase aspirin use for primary prevention of cardiovascular disease in a small city in Minnesota. Methods A community-based intervention was implemented during 16 months in a medium-sized community in Minnesota. Messages for aspirin use were disseminated to individuals, health care professionals, and the general population. Independent cross-sectional samples of residents (men aged 45-79, women aged 55-79) were surveyed by telephone to identify candidates for primary prevention aspirin use, examine their characteristics, and determine regular aspirin use at baseline and after the campaign at 4 months and 16 months. Results In primary prevention candidates, regular aspirin use rates increased from 36% at baseline to 54% at 4 months (odds ratio = 2.05; 95% confidence interval, 1.09-3.88); the increase was sustained at 52% at 16 months (odds ratio = 1.89; 95% confidence interval, 1.02-3.49). The difference in aspirin use rates at 4 months and 16 months was not significant (P=.77). Conclusion Aspirin use rates for primary prevention remain low. A combined public health and primary care approach can increase and sustain primary prevention aspirin use in a community setting.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease Advances in Diagnosis and Treatment
    Mora, Samia
    Manson, JoAnn E.
    JAMA INTERNAL MEDICINE, 2016, 176 (08) : 1195 - 1204
  • [42] Primary prevention of cardiovascular disease with aspirin: what do the guidelines say?
    Brotons Cuixart, Carlos
    Moral Pelaez, Irene
    ATENCION PRIMARIA, 2010, 42 (09): : 470 - 481
  • [43] Which people should take aspirin for primary prevention of cardiovascular disease?
    Lozano, Roberto
    Franco, Maria-Esther
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2015, 11 : 1043 - 1045
  • [44] The Heterogeneous Influences of Online Health Information Seeking on Aspirin Use for Cardiovascular Disease Prevention
    Zhu, Jingrong
    Shi, Yunfeng
    Cui, Yi
    Yan, Wei
    HEALTH POLICY AND TECHNOLOGY, 2024, 13 (02)
  • [45] Aspirin for primary prevention of stroke in individuals without cardiovascular disease-A meta-analysis
    Judge, Conor
    Ruttledge, Sarah
    Murphy, Robert
    Loughlin, Elaine
    Gorey, Sarah
    Costello, Maria
    Nolan, Aoife
    Ferguson, John
    Halloran, Martin O.
    O'Canavan, Michelle
    O'Donnell, Martin J.
    INTERNATIONAL JOURNAL OF STROKE, 2020, 15 (01) : 9 - 17
  • [46] Regular use of aspirin for cardiovascular disease prevention in Italy
    Lugo, Alessandra
    Asciutto, Rosario
    Bosetti, Cristina
    Parazzini, Fabio
    La Vecchia, Carlo
    Gallus, Silvano
    PREVENTIVE MEDICINE, 2014, 63 : 48 - 51
  • [47] Aspirin for primary prevention of cardiovascular disease in patients with diabetes: A meta-analysis
    Kokoska, Lianne A.
    Wilhelm, Sheila M.
    Garwood, Candice L.
    Berlie, Helen D.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : 31 - 39
  • [48] Aspirin in the primary prevention of cardiovascular disease: Current knowledge and future research needs
    Hennekens, Charles H.
    Dalen, James E.
    TRENDS IN CARDIOVASCULAR MEDICINE, 2014, 24 (08) : 360 - 366
  • [49] Aspirin for the primary prevention of cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis
    Pallikadavath, Susil
    Ashton, Leah
    Brunskill, Nigel J.
    Burton, James O.
    Gray, Laura J.
    Major, Rupert W.
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2022, 28 (17) : 1953 - 1960
  • [50] Recent Evidence Examining Efficacy and Safety of Aspirin for Primary Cardiovascular Disease Prevention
    Carson, Erin
    Hemenway, Alice N.
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (07) : 738 - 745